NICE backs Lucentis for impairment due to choroidal neovascularization

The U.K.'s NICE issued a final appraisal determination (FAD) recommending Lucentis ranibizumab from Novartis AG (NYSE:NVS; SIX:NOVN) to treat visual impairment due to choroidal neovascularization (CNV) secondary to pathologic myopia -- an indication the European Commission added to Lucentis' label in July. The recommendation is contingent on Novartis providing Lucentis at an undisclosed discount under a patient access scheme. Final guidance is expected next month. ...